You've heard of the popular (GLP-1) receptor agonist drug semaglutide (Ozempic, Wegovy) and GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound), but there's a new kid on the block.
November 14, 2025
A phase 3 clinical trial for retatrutide is currently underway and expected to wrap up in May 2026. After the trial is complete, the FDA usually takes 6 to 10 months to review the study once the results are submitted, says Michael Snyder, MD, the medical director of bariatric surgery at HCA HealthONE Rose in Denver, and an in-house obesity specialist at FuturHealth.
Learn more about Dr. Snyder and the team at Denver Center for Bariatric Surgery.
March 05, 2026
New CDC data shows obesity rates for adults maybe slowing, while childhood and teen rates hit record highs.
April 10, 2025
A new study found that a 4:3 intermittent fasting plan — with three days of fasting per week — helped people lose more weight than daily calorie counting.
